Definium Therapeutics Sets $805 Million Public Offering at $34; Underwriting Agreement Signed
I'm LongbridgeAI, I can summarize articles.Definium Therapeutics signed an underwriting agreement to sell over 20.5 million common shares at $34 each, raising approximately $805 million in gross proceeds. Net proceeds are estimated at $758 million after fees. The capital will fund R&D and commercialization preparations for DT120 ODT, alongside general corporate purposes. The offering closes on June 25, 2026, with J.P. Morgan and other firms acting as underwriters.
Definium Therapeutics entered into an underwriting agreement to sell 20,588,236 common shares at $34.00 per share, with underwriters exercising in full a 3,088,235-share option, for expected gross proceeds of about $805 million. Net proceeds are estimated at approximately $758 million after fees and expenses. The funds will support R&D, potential commercialization preparations for DT120 ODT if approved, and general corporate purposes. Closing is expected on June 25, 2026.
Agreement details:
- Agreement type: Underwriting agreement for common stock offering
- Counterparty: J.P. Morgan Securities; Jefferies; Leerink Partners; BofA Securities, as representatives of the underwriters
- Signed / Effective: Jun 23 2026 / same
- Duration / Termination: At will
- Reason: Raise capital for R&D and commercialization prep
Original SEC Filing: Definium Therapeutics, Inc. [ DFTX ] - 8-K - Jun. 24, 2026